Do increasing rates of loss to follow-up in antiretroviral treatment programs imply deteriorating patient retention?

American Journal of Epidemiology

Volumn 180, Issue 12, 2014, Pages 1208-1212

  Johnson, Leigh F ^a   Estill, Janne ^a   Keiser, Olivia ^a   Cornell, Morna ^a   Moolla, Haroon ^a   Schomaker, Michael ^a   Grimsrud, Anna ^a   Davies, Mary Ann ^a   Boulle, Andrew ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral treatment; HIV; Loss to follow up; Survival analysis

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIMICROBIAL ACTIVITY; DISEASE TREATMENT; IMMUNE RESPONSE; NUMERICAL MODEL; STATISTICAL ANALYSIS; SURVIVAL; VIRAL DISEASE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MORTALITY; PATIENT COMPLIANCE; PROBABILITY; SIMULATION; TREATMENT REFUSAL; COMPUTER SIMULATION; HIV INFECTIONS; MEDICATION COMPLIANCE; METHODOLOGY; STATISTICAL BIAS; SURVIVAL ANALYSIS; TIME FACTOR;

HUMAN IMMUNODEFICIENCY VIRUS;

ANTI-HIV AGENTS; BIAS (EPIDEMIOLOGY); COMPUTER SIMULATION; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; MEDICATION ADHERENCE; RESEARCH DESIGN; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84922339740     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu295     Document Type: Article

References (28)

1. Kristman V, Manno M, Côté P. Loss to follow-up in cohort studies: how much is too much? Eur J Epidemiol. 2004;19(8): 751-760.
2. Shepherd BE, Blevins M, Vaz LM, et al. Impact of definitions of loss to follow-up on estimates of retention, disease progression, and mortality: application to an HIV program in Mozambique. Am J Epidemiol. 2013;178(5):819-828.
3. Chi BH, Cantrell RA, Mwango A, et al. An empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs. Am J Epidemiol. 2010; 171(8):924-931.
4. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008;86(7):559-567.
5. Cornell M, Grimsrud A, Fairall L, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS. 2010;24(14):2263-2270.
6. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 2010;24(4):563-572.
7. Auld AF, Mbofana F, Shiraishi RW, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One. 2011; 6(4):e18453.
8. Koole O, Kalenga L, Kiumbu M, et al. Retention in a NGO supported antiretroviral program in the Democratic Republic of Congo. PLoS One. 2012;7(7):e40971.
9. Nglazi MD, Lawn SD, Kaplan R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr. 2011;56(1):e1-e8.
10. Mutevedzi PC, Lessells RJ, Newell ML. Disengagement from care in a decentralised primary health care antiretroviral treatment programme: cohort study in rural South Africa. Trop Med Int Health. 2013;18(8):934-941.
11. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10(4): e1001418.
12. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010; 15(suppl 1):1-15.
13. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4(10):e298.
14. Rosen S, Ketlhapile M. Cost of using a patient tracer to reduce loss to follow-up and ascertain patient status in a large antiretroviral therapy program in Johannesburg, South Africa. Trop Med Int Health. 2010;15(suppl 1):98-104.
15. Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health. 2011;16(10):1297-1313.
16. Ahonkhai AA, Noubary F, Munro A, et al. Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS One. 2012;7(3):e32993.
17. Ahonkhai AA, Banigbe B, Adeola J, et al. Unplanned interruptions in HIV care in Nigeria: rates and implications [abstract 1064]. Presented at the 2014 Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, March 3-6, 2014.
18. Holmes CB, Bengtson A, Sikazwe I, et al. Using the side-door: non-linear patterns within the treatment cascade in Zambia [abstract 1065]. Presented at the 2014 Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, March 3-6, 2014.
19. Kranzer K, Lewis JJ, Ford N, et al. Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr. 2010;55(3):e17-e23.
20. Yiannoutsos CT. Modeling AIDS survival after initiation of antiretroviral treatment by Weibull models with changepoints. J Int AIDS Soc. 2009;12:9.
21. Cornell M, Schomaker M, Garone D, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med. 2012; 9(9):e1001304.
22. Chi BH, Yiannoutsos CT, Westfall AO, et al. Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med. 2011;8(10):e1001111.
23. Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J. 2004;4(2):103-112.
24. Tenthani L, Haas AD, Tweya H, et al. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi. AIDS. 2014; 28(4):589-598.
25. Wei LJ, Glidden DV. An overview of statistical methods for multiple failure time data in clinical trials. Stat Med. 1997; 16(8):833-839.
26. Leisegang R, Maartens G, Hislop M, et al. A novel Markov model projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public clinics in South Africa. PLoS One. 2013;8(2): e53570.
27. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009;4(6):e5790.
28. Tweya H, Feldacker C, Estill J, et al. Are they really lost? "True" status and reasons for treatment discontinuation among HIV infected patients on antiretroviral therapy considered lost to follow up in urban Malawi. PLoS One. 2013;8(9): e75761.